Market closedNon-fractional
RxSight/RXST
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About RxSight
RxSight Inc is a commercial-stage medical technology company dedicated towards improving the vision of patients following cataract surgery. It offers intraocular lens technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery. The Company operates and manages its business in one reportable segment, the research and development, manufacture and sale of light adjustable lenses and related capital equipment.
Ticker
RXST
Sector
Healthcare
Trading on
NASDAQ
Industry
Health Care Equipment and Supplies
Headquarters
Aliso Viejo, United States
Employees
374
Website
www.rxsight.com
RxSight Metrics
BasicAdvanced
$1.8B
Market cap
-
P/E ratio
-$1.24
EPS
1.20
Beta
-
Dividend rate
Price and volume
Market cap
$1.8B
Beta
1.2
Financial strength
Current ratio
9.197
Quick ratio
8.015
Long term debt to equity
0.554
Total debt to equity
1.538
Interest coverage (TTM)
-26.37%
Management effectiveness
Return on assets (TTM)
-15.45%
Return on equity (TTM)
-28.81%
Valuation
Price to revenue (TTM)
16.022
Price to book
10.26
Price to tangible book (TTM)
10.26
Price to free cash flow (TTM)
-41.35
Growth
Revenue change (TTM)
75.67%
Earnings per share change (TTM)
-42.71%
3-year revenue growth (CAGR)
87.76%
3-year earnings per share growth (CAGR)
-31.55%
What the Analysts think about RxSight
Analyst Ratings
Majority rating from 8 analysts.
RxSight Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$30M
3.51%
Net income
-$9.1M
-0.00%
Profit margin
-30.84%
-3.38%
RxSight Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.40
-$0.35
-$0.26
-$0.25
-
Expected
-$0.47
-$0.43
-$0.36
-$0.27
-$0.20
Surprise
-14.89%
-19.23%
-28.21%
-6.10%
-
RxSight News
AllArticlesVideos
RxSight, Inc. to Report Second Quarter Financial Results on August 5, 2024
GlobeNewsWire·4 days ago
RxSight, Inc. To Participate in the Truist Securities Medtech Conference
GlobeNewsWire·2 months ago
RxSight, Inc. Announces Closing of its Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for RxSight stock?
RxSight (RXST) has a market cap of $1.8B as of July 27, 2024.
What is the P/E ratio for RxSight stock?
The price to earnings (P/E) ratio for RxSight (RXST) stock is 0 as of July 27, 2024.
Does RxSight stock pay dividends?
No, RxSight (RXST) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next RxSight dividend payment date?
RxSight (RXST) stock does not pay dividends to its shareholders.
What is the beta indicator for RxSight?
RxSight (RXST) has a beta rating of 1.2. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.
Buy or sell RxSight stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.